A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung- Map Sub-Study)

Trial Profile

A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung- Map Sub-Study)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Erlotinib (Primary) ; Rilotumumab (Primary)
  • Indications Lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms Lung-MAP Sub-Study
  • Most Recent Events

    • 18 Oct 2017 Results of Lung-Map substudies (S1400A, B, C, D and E) presented at the 18th World Conference on Lung Cancer
    • 12 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top